The Paradigm Evolves
November 13 – 14, 2019 • Harvard Medical School, Boston, MA
The 15th Annual Personalized Medicine Conference at Harvard Medical School will explore the science, business, and policy issues facing personalized medicine as scientists refine their understanding of how groundbreaking molecular diagnostics augmented by artificial intelligence, advanced data analytics, and digital health applications can empower both physicians and patients with information about how an expanded set of biological characteristics — including those found in the proteome and microbiome — may influence their health and their responses to increasingly impactful therapies.
With gene therapies, cell-based regenerative medicine, more targeted therapies, and the introduction of better tools for delivering therapies from digital health apps to artificial intelligence to next-generation sequencing, we’re living in an age of momentous progress and rapid cycles of innovation.”— Scott Gottlieb, M.D., Resident Fellow, American Enterprise Institute
With new biomarkers coming on line, we probably will be able to diagnose much better who will respond best to therapy. That means we have to develop drugs and diagnostics together.”— Paul Stoffels, M.D., Vice Chairman, Executive Committee, Chief Scientific Officer, Johnson & Johnson
It is important that the research, medical, and pharmaceutical communities collaborate to maintain momentum in personalized medicine so that we are able to deliver cutting-edge care and clinical trial opportunities to all patients.”— Carl June, M.D., Richard W. Vague Professor in Immunotherapy, University of Pennsylvania
Bonnie J. Addario
GO2 Foundation for Lung Cancer
Scott Gottlieb, M.D.
American Enterprise Institute
Carl June, M.D.
Richard W. Vague Professor in Immunotherapy
University of Pennsylvania
Nancy Mendelsohn, M.D.
Chief Medical Officer, Special Needs Initiative
Joshua Ofman, M.D.
Chief of Corporate Strategy and External Affairs
Steven Shak, M.D.
Chief Scientific Officer
Kenna R. Mills Shaw, Ph.D.
MD Anderson Institute for Personalized Cancer Therapy
Paul Stoffels, M.D.
Vice Chairman, Executive Committee; Chief Scientific Officer
Johnson & Johnson